摘要:
An opening and closing apparatus for a lid including a box body, a lid openable and closable in a first direction and a second direction relative to the box body, a movable member movable to a first position for opening the lid in the first direction, a second position for opening the lid in the second direction, and a closing position for closing the lid, first and second operating buttons integrally coupled to the opposite end portions of the movable member, a first biasing member for normally biasing the movable member to the closing position, and a holding member for holding the movable member in the first position against the biasing force of the first biasing member when the first operating button is pressed and the movable member is moved to the first position, and holding the movable member in the second position against the biasing force of the first biasing member when the second operating button is pressed and the movable member is moved to the second position, the holding member being disposed near the edge of the lid extending parallel to the first and second directions, the movable member being disposed off the center of the lid and near the holding member.
摘要:
An object and project of the present invention is to provide a method for producing silicon fine particles and a method for controlling a particle diameter of silicon fine particles which enable efficient production of silicon fine particles having a uniform particle diameter. A the characteristics of the present invention is producing silicon fine particles having a smaller particle diameter than silicon particles and controlling a particle diameter of silicon fine particles by immersing the silicon particles into an etching solution and irradiating the silicon particles immersed in the etching solution with light having a larger energy than a band gap energy of the silicon particles.
摘要:
To provide a novel JAK3 inhibitor that is useful as a preventive and/or therapeutic agent for rejection and graft versus host disease (GvHD) in organ transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sjögren syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic rhinitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia and the like. The pyridine-3-carboxyamide derivative represented by the general formula (1): or its salt or a solvate thereof.
摘要:
The inventors of this invention have conducted the search for a variety of compounds which may possess a desired CaSR agonist activity to thus find out a substance capable of imparting a kokumi, which shows a more excellent kokumi-imparting effect, in particular, a kokumi-imparting effect of the initial taste-imparting type one, which is excellent in the stability and which can easily be produced at a low cost and the present invention thus provide a kokumi-imparting agent consisting of such a substance as well as a complex kokumi-imparting agent comprising the substance and other substances possessing the CaSR agonist activities in combination. More particularly, the present invention herein provides a kokumi-imparting agent consisting of γ-Glu-Abu (L-γ-glutamyl-L-2-amino-butyric acid) and a complex kokumi-imparting agent comprising the foregoing substance and another substance having a CaSR agonist activity, in combination.
摘要:
Disclosed is a compound which has both an angiotensin-II receptor antagonistic activity and a PPARγ activation activity and is useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, angina pectoris, cerebrovascular disorders, cerebral circulatory disorders, ischemic peripheral circulatory disorders, renal diseases, arteriosclerosis, inflammatory diseases, type-2 diabetes, diabetic complications, insulin resistance syndrome, syndrome X, metabolic syndrome and hyperinsulinemia. [In the formula, A represents a 5- to 10-membered heteroaryl group; R1 and R2 independently represent a C1-6 alkyl group; and each of R3 to R5 is absent or represents H, a halogen atom, OH, NO2, a halo-C1-6 alkyl group, a (substituted) C1-6 alkoxy group, a (substituted) C3-6 cycloalkyloxy group, or a 5- to 10-membered heteroaryl group.]
摘要:
A battery box structure includes a battery module, a holding frame which holds the battery module, a case which is made from expanded insulating resin and which stores the holding frame, and an elastic member secured to the holding frame and arranged between the battery module and the case, wherein the elastic member includes an upper wall and flanges extending from both side edges of the upper wall, and wherein a distance between the flanges is substantially the same as a width of a protrusion of the holding frame for securing the elastic member to the holding frame.
摘要:
The present invention relates a specific tetrahydroisoquinoline compound which is useful as a chemokine receptor type 3 (CCR3) antagonist, and a pharmaceutical composition comprising the same as an active ingredient. The tetrahydroisoquinoline compound of the present invention is useful for the treatment or prevention of a disease in which CCR3 participates.
摘要:
A battery box housing a battery is mounted between left and right side frames extending in a longitudinal direction of a vehicle body so that the battery box is offset to a left side of the vehicle body, and an intake duct and an exhaust duct for cooling air for cooling the battery are connected to an end of the battery box on a right side of the vehicle body. Therefore, it is possible not only to protect the battery between the left and right frames from a shock caused upon a side collision, but also to ensure a space for disposition of the intake duct and the exhaust duct while ensuring a volume of the battery box to the maximum. Moreover, the battery box is connected at its left and right ends to the left and right side frames.
摘要:
Compounds having the formula (1): wherein R1 represents an alkyl or alkenyl group, R2 and R3 each independently represents a hydrogen atom or an alkyl, hydroxyalkyl, dihydroxyalkyl or alkynyl group, or R2 and R3 may be fused together with the adjacent nitrogen atom to form a substituted or unsubstituted, nitrogen-containing, saturated heterocyclic group, X, Y and Z each independently represents a hydrogen atom, an alkyl group, a halogen atom or the like, and n stands for an integer of from 1 to 5; and also to pharmaceutical compositions containing them. These compounds have inhibitory activity against IL-1β production, high water solubility and good oral absorbability.